Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $36.7 million.

  • Cytosorbents' Total Liabilities rose 597.49% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year increase of 597.49%. This contributed to the annual value of $36.3 million for FY2024, which is 2303.6% up from last year.
  • Per Cytosorbents' latest filing, its Total Liabilities stood at $36.7 million for Q3 2025, which was up 597.49% from $36.4 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Total Liabilities ranged from a high of $36.7 million in Q3 2025 and a low of $10.2 million during Q1 2021
  • In the last 5 years, Cytosorbents' Total Liabilities had a median value of $27.9 million in 2022 and averaged $28.7 million.
  • As far as peak fluctuations go, Cytosorbents' Total Liabilities crashed by 5539.54% in 2021, and later skyrocketed by 17243.96% in 2022.
  • Over the past 5 years, Cytosorbents' Total Liabilities (Quarter) stood at $26.9 million in 2021, then grew by 3.4% to $27.9 million in 2022, then grew by 5.81% to $29.5 million in 2023, then grew by 23.04% to $36.3 million in 2024, then grew by 1.28% to $36.7 million in 2025.
  • Its Total Liabilities was $36.7 million in Q3 2025, compared to $36.4 million in Q2 2025 and $36.2 million in Q1 2025.